Dohaekseunggi-tang extract inhibits obesity, hyperlipidemia, and hypertension in high-fat diet-induced obese mice

BMC Complementary and Alternative Medicine

Ho Kyoung Kim¹  Seung-Hyung Kim²  Goya Choi¹  Dong-Seon Kim¹  Yoon-Young Sung¹ 

[1] Herbal Medicine Resources Group, Herbal Medicine Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 305-811, Republic of Korea;Institute of Traditional Medicine and Bioscience, Daejeon University, Daejeon 300-716, Republic of Korea

关键词: Visceral adipose tissue;    Pancreatic lipase;    High-fat diet;    Dohaekseunggi-tang;    Body weight;    Angiotensin-1 converting enzyme;   

Others  :  1086397
DOI  :  10.1186/1472-6882-14-372

 received in 2014-04-29, accepted in 2014-09-24,  发布年份 2014

【 摘 要 】

Background

Dohaekseunggi-tang (DHSGT) is a traditional plant-based medicine prescribed to promote blood circulation and to treat obesity and hypertension. The present study aimed to identify potential anti-obesity activities of DHSGT extract.

Methods

Anti-obesity, anti-hyperlipidemic, and anti-hypertensive effects of orally-administered DHSGT extract were evaluated in high-fat diet- (HFD)-induced obese mice. Serum biochemistry profiles and expression of diverse metabolic regulatory gene mRNAs in mouse visceral fat were assessed by RT-PCR. The effects of DHSGT on angiotensin-1 converting enzyme (ACE) and pancreatic lipase activities were determined using in vitro inhibition assays.

Results

Oral DHSGT treatment reduced obese HFD C57BL/6 J mouse body weight, liver and adipose tissue mass, adipocyte size, and blood pressure versus untreated HFD mice. DHSGT also decreased serum total cholesterol, LDL-cholesterol, triglyceride, glucose, and leptin concentrations, and increased HDL-cholesterol and adiponectin levels in HFD mice. Furthermore, DHSGT markedly increased mRNA expression of peroxisome proliferator activated receptor-gamma, uncoupling protein-2, and adiponectin in visceral adipose tissue of HFD mice. In vitro tests revealed that DHSGT effectively inhibited porcine pancreatic lipase and ACE activities, with IC₅₀ values of 7.58 mg/ml and 0.56 mg/ml, respectively.

Conclusions

These results validate traditional knowledge and suggest that DHSGT may be potentially useful for managing hyperlipidemia, hyperglycemia, hypertension, and obesity.

【 授权许可】

   
2014 Sung et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Son Y, Nam JS, Jang MK, Jung IA, Cho SI, Jung MH: Antiobesity activity of Vigna nakashimae extract in high-fat diet-induced obesity. Biosci Biotechnol Biochem 2013, 77(2):332-338.
• [2]Medina-Gomez G, Vidal-Puig A: Gateway to the metabolic syndrome. Nat Med 2005, 11(6):602-603.
• [3]Song MY, Chung SH, Lee JS, Kim SS, Shin HD: The study on pharmacological treatment of obesity in western and oriental medicine. J Oriental Med 1999, 4(1):55-65.
• [4]Yun JW: Possible anti-obesity therapeutics form nature-A review. Phytochemisty 2010, 71:1625-1641.
• [5]Kim YS, Lee Y, Kim J, Sohn E, Kim CS, Lee YM, Jo K, Shin S, Song Y, Kim JH, Kim JS: Inhibitory activities of Cudrania tricuspidata leaves on pancreatic lipase in vitro and lipolysis in vivo. Evid Based Complement Alternat Med 2012, 2012:878365. doi: 10.1155/2012/878365
• [6]Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS: Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008, 31(1):53-65.
• [7]Birari RB, Bhutani KK: Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov Today 2007, 12(19–20):879-889.
• [8]Kang YY: Treatment of obesity in Chinese medicine. J Peijing Chin Med Coll 1985, 8:26.
• [9]Wang WJ: Prevention and treatment of metabolic syndrome with integrated traditional Chinese and western medicine. Zhong Xi Yi Jie He Xue Bao 2004, 2(5):390-395.
• [10]Lai TY, Weng YJ, Kuo WW, Chen LM, Chung YT, Lin YM, Tsai FJ, Lee CH, Choong YM, Lai EY, Huang CY, Yeh YL: Taohe Chengqi Tang ameliorates acute liver injury induced by carbon tetrachloride in rats. Zhong Xi Yi Jie He Xue Bao 2010, 8(1):49-55.
• [11]Korean Medicine College: Circulation of Oriental Medicine·Neurological Medicine. Korea: Kunja Press; 2010:171-178.
• [12]Chen Q: Pharmacology and Application of Chinese Herbs. Taiwan: SMC; 1989:451.
• [13]Kim JB, Choi SH, An KS: Study of the effects of Taorenchengqitang and its components on blood stasis model. Korean J Oriental Physiol Pathol 1997, 11:65-76.
• [14]Yoon JJ, Lee YJ, Park OJ, Lee SM, Lee YP, Cho NG, Kang DG, Lee HS: Doinseunggitang ameliorates endothelial dysfunction in diabetic atherosclerosis. Evid Based Complement Alternat Med 2013, 2013:783576. doi:10.1155/2013/783576
• [15]Jeong JH: The effects of Dohaeksungitang on the weight and lipid metabolism of induced obesity rats. MA thesisHyung Hee University, Department of Oriental Medicine;1993
• [16]Lee YJ, Kin EK, Kim HY, Yoon JJ, Lee SM, Lee GM, Kang DG, Lee HS: Therapeutic effect of Doinseunggi-tang on diabetic vascular dysfunction. Herb Formul Sci 2013, 21(1):119-130.
• [17]Furukawa I, Kurooka S, Arisue K, Kohda K, Hayashi C: Assays of serum lipase by the “BALB-DTNB method” mechanized for use with discrete and continuous-flow analyzers. Clin Chem 1982, 28(1):110-113.
• [18]Harp JB: New insights into inhibitors of adipogenesis. Curr Opin Lipidol 2004, 15(3):303-307.
• [19]Fasshauer M, Paschke R: Regulation of adipocytokines and insulin resistance. Diabetologia 2003, 46(12):1594-1603.
• [20]Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257(1):79-83.
• [21]Maffei M, Halaas J, Ravussin E, Pratley RE, LeeGH ZY, Fei H, Kim S, Lallone R, Ranganathan S, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S: Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995, 1(11):1155-1161.
• [22]Shin SS, Jung YS, Yoon KH, Choi S, Hong Y, Park D, Lee H, Seo BI, Lee HY, Yoon M: The Korean traditional medicine gyeongshingangjeehwan inhibits adipocyte hypertrophy and visceral adipose tissue accumulation by activating PPARalpha actions in rat white adipose tissues. J Ethnopharmacol 2010, 127(1):47-54.
• [23]Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996, 1302(2):93-109.
• [24]Vidal-Puig A1, Jimenez-Liñan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller D: Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996, 97(11):2553-2561.
• [25]Chandran M, Phillips SA, Ciaraldi T, Henry RR: Adiponectin: more than just another fat cell hormone? Diabetes Care 2003, 26(8):2442-2450.
• [26]Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002, 51(10):2968-2974.
• [27]Kersten S: Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 2002, 440(2–3):223-234.
• [28]Andrews ZB, Erion DM, Beiler R, Choi CS, Shulman GI, Horvath TL: Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology 2010, 151(5):2078-2086.
• [29]Lowe ME: Pancreatic triglyceride lipase and colipase: insights into dietary fat digestion. Gastroenterology 1994, 107(5):1524-1536.
• [30]Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2003, 289(1):76-79.
• [31]Rüster C, Wolf G: The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol 2013, 33(1):44-53.
• [32]Xie Y, Zhang W: Antihypertensive activity of Rosa rugosa Thunb. flowers: angiotensin I converting enzyme inhibitor. J Ethnopharmacol 2012, 144(3):562-566.
• [33]Thethi T, Kamiyama M, Kobori H: The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 2012, 14(2):160-169.
• [34]Frigolet ME, Torres N, Tovar AR: The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem 2013, 24(12):2003-2015.